profit from every $100 of sales.
$0$100
Matinas BioPharma Holdings
$1.23-0.81% today
+5.1% in 1 year
1-year low $0.491-year high $13.08
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Matinas BioPharma Holdings sold, what it kept, and what it did with the cash.
Sales went from $3.19 million in 2022 to $0 in 2025, with -$10.3 million of profit last year.
SalesProfit
Matinas BioPharma Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Matinas BioPharma Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Matinas BioPharma Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3 | 1 | 0 | 0 | |
| – | – | – | – | |
| -25 | -24 | -20 | -7 | |
| -24 | -23 | -19 | -7 | |
| -21 | -23 | -24 | -10 | |
| -5.00 | -5.28 | -4.98 | -2.00 | |
| – | – | – | – | |
| -771.3% | -2,168.4% | – | – | |
| -658.6% | -2,093.2% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 45 | 25 | 13 | 7 |
| Cash | 7 | 5 | 7 | 4 |
| Total debt | 4 | 4 | 3 | 1 |
| Total liabilities | 8 | 6 | 5 | 2 |
| 37 | 19 | 8 | 5 | |
| 4 | 4 | 5 | 5 | |
| -47.7% | -82.3% | -151.9% | -88.9% | |
| -57.3% | -119.2% | -319.5% | -214.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -15 | -16 | -7 | |
| 1 | 0 | – | – | |
| -20 | -15 | -16 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 5 | 3 | 1 |
Valuation
- –
- –
- –
- 1.4×
- 1.1×
- –
- –
- -1,286.2%
- -1,904.2%
- 0.0%
Profitability
- 0.0%
- -2,168.4%
- -2,093.2%
- 0.0%
- -155.6%
- -118.3%
- -204.3%
- -191.1%
- -185.4%
- –
Growth
- −65.6%
- –
- +55.9%
- –
- +6.8%
Financial health
- -0.1×
- 0.39
- 20.2%
- –
- 1.32
- 1.32
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -0.30 | -1.32 | +77.2% |
| Mar 31, 2026 | -0.30 | -0.78 | +61.5% |
| Nov 10, 2025 | -0.40 | – | – |
| Aug 14, 2025 | -1.03 | – | – |
| Apr 15, 2025 | -1.68 | -0.78 | −115.4% |
| Mar 26, 2025 | -1.50 | -0.78 | −92.3% |
| Nov 13, 2024 | -0.85 | -1.05 | +19.0% |
| Aug 14, 2024 | -1.00 | -0.83 | −20.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
49No pass
Philip Fisher
31No pass
Peter Lynch
17No pass
Joel Greenblatt
0No pass
Charlie Munger
21No pass
Terry Smith
18No pass
Questions about Matinas BioPharma Holdings
Is Matinas BioPharma Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Matinas BioPharma Holdings AI analysis
What does Matinas BioPharma Holdings do?
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. It is in Biotechnology.
Does Matinas BioPharma Holdings pay a dividend?
No. Matinas BioPharma Holdings does not pay a dividend at the moment.
Is Matinas BioPharma Holdings stock halal?
No. Matinas BioPharma Holdings does not pass our halal screen: its debt is 112% of its market value, at or above the 33% limit. How we check
How has Matinas BioPharma Holdings stock done over the past year?
Up 5.1% over the past twelve months, to $1.23. It traded between $0.49 and $13.08 and is 90.6% below its high.
Who are Matinas BioPharma Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Matinas BioPharma Holdings's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.